EVLO - エベロ・バイオサイエンシズ （Evelo Biosciences Inc.） エベロ・バイオサイエンシズEVLOのチャート
EVLOの企業情報
| symbol | EVLO |
|---|---|
| 会社名 | Evelo Biosciences Inc （エベロ・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Evelo Biosciences Inc. is engaged in developing therapies designed to act on gut-body network. The Company develops monoclonal microbes that are orally-delivered compositions of specific strains of naturally occurring microbes derived from a single clone. Its principal product candidates include EDP1066 EDP1815 and EDP1503 that are in the pre-clinical development stage. EDP1066 and EDP1815 are monoclonal microbial product candidates that are developed to treat inflammatory diseases that include psoriasis atopic dermatitis rheumatoid arthritis and ulcerative colitis. EDP1503 is the Company's product candidate developed under oncology portfolio to treat diseases such as colorectal cancer renal cell carcinoma and melanoma among others. エベロ・バイオサイエンシズは米国のバイオ医薬品企業。主にマイクロバイオ―ムによる、がん、自己免疫および炎症性疾患に対する免疫療法の開発に従事する。同社は、がん治療のためのオンコマイシンを開発。また、アトピ―性皮膚炎、関節リウマチ、潰瘍性大腸炎、結腸直腸がん、腎細胞がん、メラノ―マなどの免疫療法に焦点を当てる。本社所在地はマサチュ―セッツ州ケンブリッジ。 Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company's first product candidates are pharmaceutical preparations of single strains of microbes selected for the potential to offer defined pharmacological properties. Evelo's therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer. |
| 本社所在地 | 620 Memorial Drive Suite 200 Cambridge MA 02139 USA |
| 代表者氏名 | Noubar B. Afeyan Noubar B. Afeyan |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 617-870-8281 |
| 設立年月日 | 41760 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | 59人 |
| url | www.evelobio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/evlo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） ー |
| 終値（lastsale） | 11.65 |
| 時価総額（marketcap） | 369789663.3 |
| 時価総額 | 時価総額（百万ドル） 360.26720 |
| 売上高 | 売上高（百万ドル） -- |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 196.11820 |
| 当期純利益 | 当期純利益（百万ドル） -- |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Evelo Biosciences Inc revenues was not reported. Net loss applicable to common stockholders increased from $14.4M to $29.6M. Higher net loss reflects Research and development - Balancing increase of 96% to $16.3M (expense) General and administrative - Balancing increase from $2.6M to $6.4M (expense) Stock-based Compensation in SGA increase from $256K to $1.9M (expense). |
EVLOのテクニカル分析
EVLOのニュース
Evelo Biosciences to Participate in the Cowen 43rd Annual Health Care Conference 2023/03/01 11:00:00 GlobeNewswire
CAMBRIDGE, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a novel platform of orally delivered anti-inflammatory medicines acting on the small intestinal axis, SINTAX, today announced that Mark Plinio, J.D., Chief Commercial Officer will participate in a dermatology panel at the Cowen 43 rd Annual Health Care Conference on Tuesday, March 7, 2023 at 12:50 p.m. ET.
Evelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis Trial 2023/02/27 11:00:00 GlobeNewswire
– Completed first blinded, placebo-controlled cohort in human volunteers with no safety or tolerability concerns –
Evelo Biosciences Inc PT Lowered to $2 at Morgan Stanley 2023/02/15 13:13:06 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-2-at-morgan-stanley-432SI-3004105
Morning Volatile Movements: Phunware, Inc. (NASDAQ:PHUN 0.47%), Evelo Biosciences, Inc. (NASDAQ:EVLO -0.81%) 2023/02/13 18:19:30 Stock Equity
PHUN has seen its SMA50 which is now 3.95%. In looking the SMA 200 we see that the stock has seen a -20.98%. EVLO has seen its SMA50 which is … The post Morning Volatile Movements: Phunware, Inc. (NASDAQ:PHUN 0.47%), Evelo Biosciences, Inc. (NASDAQ:EVLO -0.81%) appeared first on Stocks Equity .
Evelo Biosciences Inc PT Lowered to $10 at BMO Capital 2023/02/06 17:47:02 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-10-at-bmo-capital-432SI-2996349
Evelo Biosciences Inc PT Lowered to $10 at BMO Capital 2023/02/06 17:47:02 Investing.com
https://www.investing.com/news/pro/evelo-biosciences-inc-pt-lowered-to-10-at-bmo-capital-432SI-2996349
Evelo Biosciences'' Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response Rates 2023/02/01 17:53:00 Benzinga
Evelo Biosciences Inc (NASDAQ: EVLO ) said it observed an unusually high placebo response rate in the first three cohorts of the EDP1815 Phase 2 atopic dermatitis study, resulting in a missed primary endpoint . The company said it is working through the data to understand the very high placebo rates observed in the trial, which occurred with greater prevalence in certain geographic regions. The trial''s fourth cohort, designed to test the … Full story available on Benzinga.com
Evelo Biosciences Collapses after Treatment Trial Fails 2023/02/01 17:40:33 TipRanks
Shares of biotech stock Evelo Biosciences (NASDAQ:EVLO) collapsed in today’s trading session. This can be attributed to the company’s eczema treatm…
Jefferies Downgrades Evelo Biosciences Inc to Underperform 2023/02/01 17:23:01 Investing.com
https://www.investing.com/news/pro/jefferies-downgrades-evelo-biosciences-inc-to-underperform-432SI-2993449
Quoin, F-star top healthcare gainers; Evelo, Taysha lead losers'' pack 2023/02/01 15:03:04 Seeking Alpha
Quoin Pharmaceuticals (QNRX) +49%. F-star Therapeutics (FSTX) +15%. Evelo Biosciences (EVLO) -24%. Taysha Gene Therapies (TSHA) -24%.
Evelo Biosciences GAAP EPS of -$0.28 in-line 2022/11/15 13:47:12 Seeking Alpha
Evelo Biosciences press release (EVLO): Q3 GAAP EPS of -$0.28 in-line.As of September 30, 2022, cash and cash equivalents were $69.1M, as compared to cash and cash equivalents of…
Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business Highlights 2022/11/14 22:27:00 GlobeNewswire
- Multiple Phase 2 readouts for EDP1815 in atopic dermatitis expected in 2023; data from first three cohorts expected in early 1Q 2023 and fourth cohort in 2Q 2023 -
Have you been able to find a good deal on Evelo Biosciences Inc.’s shares? 2022/09/19 15:48:00 US Post News
The share price of Evelo Biosciences Inc. (NASDAQ:EVLO) fell to $2.11 per share on Friday from $2.12. While Evelo Biosciences Inc. has underperformed by -0.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EVLO fell by -71.14%, with highs and lows ranging from $12.74 to $1.42, […]
Evelo Biosciences (EVLO) Investor Presentation - Slideshow (NASDAQ:EVLO) 2022/09/16 22:15:36 Seeking Alpha
The following slide deck was published by Evelo Biosciences, Inc.
Do investors need to be concerned about Evelo Biosciences Inc. (EVLO)? 2022/09/05 15:40:00 US Post News
As of Friday, Evelo Biosciences Inc.’s (NASDAQ:EVLO) stock closed at $2.41, up from $2.29 the previous day. While Evelo Biosciences Inc. has overperformed by 5.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, EVLO fell by -78.60%, with highs and lows ranging from $12.74 to $1.42, […]